- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00595244
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease
July 1, 2008 updated by: Point Biomedical
CSP 127-006 A Phase 3 Clinical Trial to Assess Perfusion and Obstruction Identified by Non-Invasive Technology Using PB127 Ultrasound Contrast Agent in Patients With Suspected Obstructive Coronary Arter Disease
This trial is to compare PB127 echocardiography to other heart imaging studies.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
456
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85018
- Michael Morgan, MD
-
-
California
-
Long Beach, California, United States, 90822
- Long Beach VA Medical Center Cardiology Division
-
San Diego, California, United States, 92103
- University of California San Diego Division of Cardiology
-
San Francisco, California, United States, 94121
- San Francisco VA Medical Center NCIRE
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Hospital Center Cardiovascular Research Institute
-
-
Kansas
-
Shawnee Mission, Kansas, United States, 66204
- The Center for Cardiovascular Studies Kramer & Crouse Cardiology
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- New England Medical Center
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- St. Louis University Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- The Cleveland Clinic Foundation Department of Cardiology
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health Sciences University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Cardiovascular Institute
-
-
Texas
-
San Antonio, Texas, United States, 78229
- University of Texas Health Sciences Center at San Antonio
-
-
Washington
-
Seattle, Washington, United States, 98101
- Virginia Mason Medical Center
-
Seattle, Washington, United States, 98104
- Harborview Medical Center Department of Cardiology
-
Spokane, Washington, United States, 99204
- Northwest Cardiovascular Research Institute Spokane Cardiology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Stratum 1:
- Able to provide written informed consent
- Low (less than 10%) pre-test probability of CAD (Appendix D)
- Scheduled for clinically indicated stress echocardiography or stress SPECT within the 14 days prior to or following Study Day 1 (prior to coronary angiography) or coronary angiography within the 7 days following Study Day 1
- Technically adequate unreconstructed stress SPECT data or scheduled for clinically indicated stress SPECT within 14 days of Study Day 1 and prior to coronary angiography
- Adequate visualization of all myocardial segments in at least one view during non-contrast echocardiography (See Section 5.3.1)
- No evidence of a right-to-left shunt during non-contrast echocardiography
Stratum 2:
- Able to provide written informed consent
- Intermediate (10% to 90%) pre-test probability of CAD (Appendix D)
- Scheduled for clinically indicated coronary angiography within the 7 days following Study Day 1
- Technically adequate unreconstructed stress SPECT data or scheduled for stress SPECT within 14 days of Study Day 1 and prior to coronary angiography
- Adequate visualization of all myocardial segments in at least one view during non-contrast echocardiography (See Section 5.3.1)
- No evidence of a right-to-left shunt during non-contrast echocardiography
Stratum 3:
- Able to provide written informed consent
- High (greater than 90%) pre-test probability of CAD (Appendix D)
- Scheduled for clinically indicated coronary angiography within the 7 days following Study Day 1
- Technically adequate unreconstructed stress SPECT data or scheduled for stress SPECT within 14 days of Study Day 1 and prior to coronary angiography
- Adequate visualization of all myocardial segments in at least one view during non-contrast echocardiography (See Section 5.3.1)
- No evidence of a right-to-left shunt during non-contrast echocardiography
Exclusion Criteria:
- Women who are pregnant or lactating
Known hypersensitivity or known contraindication to:
- Dipyridamole
- Ultrasound contrast agents (including PB127 and excipients)
- Blood, blood products, albumin, egg, or protein
- Use of caffeine or xanthine containing products within the 24 hours prior to PB127 MCE
- Previous exposure to PB127 Ultrasound Contrast Agent
- Heart transplant
- Known right-to-left shunt including atrial septal defect
- Current or history of uncontrolled ventricular tachycardia
- Current atrial fibrillation, atrial tachycardia, or atrial flutter
- Pacemaker or defibrillator
Unstable cardiac status
- Unstable angina grade CCS Class IV severity with ongoing symptoms and/or ongoing infusion of intravenous nitroglycerin (See Appendix F)
- Second-degree or greater heart block
- Frequent (>60/hour) or symptomatic ventricular ectopics at baseline
- Hypertension (SPB >200 and/or DBP >110 mmHg on two consecutive readings within one hour of PB127 MCE)
- Hypotension (SPB <90 mmHg)
- Severe aortic stenosis (>100 mmHg peak transvalvar gradient or <0.6 cm2 estimated valve area)
- Pulmonary edema within the 7 days prior to Study Day 1
- Resting oxygen saturation of less than 90%
- Q-wave myocardial infarction within the 7 days prior to Study Day 1
- PTCA or CABG within the 7 days prior to Study Day 1
- Chronic Obstructive Pulmonary Disease (COPD) or bronchospastic airway disease which, in the opinion of the Investigator, is significant enough to contraindicate dipyridamole
- Known history of severe pulmonary hypertension characterized by estimated pulmonary artery systolic pressure of >50 mmHg
- Use of intravenous or intracoronary contrast agent other than thallium or technetium within the 24 hours prior to Study Day 1
Liver disease (i.e., current or previous hepatic viral infection, chronic hepatitis) characterized by one or more of the following
- Current jaundice
- Elevated bilirubin > upper limit of normal
- Currently elevated hepatic enzymes > 2X upper limit of normal
- Medical conditions or other circumstances that would significantly decrease the chances of obtaining reliable data or achieving the study objectives (i.e., drug dependence, psychiatric disorder, dementia, or associated illness), extenuating circumstances, medical conditions that make it unlikely that a patient can complete the clinical trial or follow-up evaluations, or other reasons for expected poor compliance with the Investigator's instructions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To demonstrate the non-inferiority of the diagnostic performance of PB127 MCE versus stress SPECT in the detection and/or exclusion of significant obstructive CAD as defined by QCA or qualifying clinical outcome.
Time Frame: 90 days
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the concordance of PB127 MCE with stress SPECT in differentiating between reversible vs. fixed defects in patients with significant obstructive CAD
Time Frame: 28 days
|
28 days
|
To compare the diagnostic performance of PB127 MCE with stress SPECT in identifying the location of stenosis as identified by coronary angiography.
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Alexander Ehlgen, MD, PhD, POINT Biomedical Corp.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2002
Primary Completion (Actual)
October 1, 2003
Study Completion (Actual)
October 1, 2003
Study Registration Dates
First Submitted
January 7, 2008
First Submitted That Met QC Criteria
January 7, 2008
First Posted (Estimate)
January 16, 2008
Study Record Updates
Last Update Posted (Estimate)
July 3, 2008
Last Update Submitted That Met QC Criteria
July 1, 2008
Last Verified
July 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 127-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
Clinical Trials on PB127 for injectable suspension
-
Point BiomedicalCompletedCoronary Artery DiseaseUnited States
-
Point BiomedicalTerminatedCoronary Artery Disease | HealthyUnited States
-
Point BiomedicalCompletedCoronary Artery DiseaseUnited States
-
Point BiomedicalTerminatedCoronary Artery DiseaseUnited States
-
Point BiomedicalCompletedCoronary Artery Disease | HealthyUnited States
-
Lantheus Medical ImagingCompletedVentricular Ejection FractionUnited States
-
NantBioScience, Inc.WithdrawnNeoplastic DiseaseUnited States
-
Zafgen, Inc.CompletedObesity | Prader-Willi Syndrome | Over-weightUnited States
-
GE HealthcareICON Clinical ResearchCompletedPulmonary HypertensionUnited States
-
Zafgen, Inc.TerminatedObesity | Type 2 DiabetesAustralia